Table 2 Relationship between nuclear ADA3 and nuclear c-MYC co-expression groups and clinico-pathological parameters within the whole unselected invasive breast cancer series (n = 588 cases)
From: ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC
Parameters | ADA3 Nuclear c-MYC Nuclear expression phenotypes | ||||||
|---|---|---|---|---|---|---|---|
ADA3low c-MYClow N (%) | ADA3high c-MYClow N (%) | ADA3low c-MYChigh N (%) | ADA3high c-MYChigh N (%) | X 2 | P | ||
Patient age | ≤50 | 66 (31.7) | 24 (11.5) | 65 (31.1) | 53 (25.5) | 1.862 | 0.602 |
>50 | 106 (28.0) | 45 (11.9) | 113 (29.8) | 115 (30.3) | |||
Menopausal Status | Pre | 66 (30.4) | 25 (11.5) | 68 (31.3) | 58 (26.7) | 0.907 | 0.871 |
Post | 106 (28.6) | 44 (11.9) | 110 (29.7) | 110 (29.7) | |||
Tumor size | ≤2 cm | 96 (28.0) | 14 (12.0) | 99 (28.9) | 107 (31.2) | 2.765 | 0.429 |
>2Â cm | 76 (31.4) | 28 (11.6) | 77 (31.8) | 61 (25.2) | |||
Tumor grade | 1 | 20 (23.5) | 14 (16.6) | 17 (20.0) | 34 (40.0) | 32.961 | <0.001 |
2 | 47 (25.3) | 18 (9.7) | 48 (25.8) | 73 (39.2) | |||
3 | 105 (33.3) | 37 (11.7) | 112 (35.4) | 62 (19.6) | |||
Tubules | 1 | 5 (22.7) | 7 (31.8) | 5 (22.7) | 5 (22.7) | 13.345 | 0.037 |
2 | 47 (25.1) | 21 (11.2) | 59 (31.6) | 60 (32.1) | |||
3 | 116 (32.7) | 35 (9.9) | 107 (30.1) | 97 (27.3) | |||
Pleomorphism | 1 | 1 (14.3) | 1 (14.3) | 3 (42.9) | 2 (28.6) | 29.138 | <0.001 |
2 | 57 (26.0) | 31 (14.2) | 46 (21.0) | 85 (38.8) | |||
3 | 110 (32.6) | 31 (9.2) | 122 (36.2) | 74 (22.0) | |||
Mitosis | 1 | 43 (24.6) | 23 (13.1) | 40 (22.9) | 69 (39.4) | 23.706 | 0.001 |
2 | 30 (29.1) | 9 (8.7) | 30 (29.1) | 34 (33.0) | |||
3 | 95 (33.2) | 31 (10.8) | 101 (35.3) | 59 (20.6) | |||
Axillary nodal stage | 1 | 93 (28.5) | 42 (12.9) | 90 (27.6) | 101 (31.0) | 6.617 | 0.353 |
2 | 57 (28.2) | 23 (11.4) | 68 (33.7) | 54 (26.7) | |||
3 | 22 (37.3) | 4 (6.8) | 20 (33.9) | 13 (22.0) | |||
NPI | Good | 30 (19.2) | 21 (13.5) | 39 (4) | 66 (25.0) | 33.968 | <0.001 |
Moderate | 103 (33.0) | 40 (12.8) | 88 (8.8) | 81 (28.2) | |||
Poor | 39 (33.1) | 8 (6.8) | 50 (36) | 21 (17.8) | |||
Lymphovascular Invasion | Negative | 106 (28.0) | 52 (13.8) | 103 (27.2) | 117 (31.0) | 10.624 | 0.014 |
Positive | 64 (31.4) | 16 (7.8) | 75 (36.8) | 49 (24.0) | |||
Tumor type | Invasive Ductal/NST | 123 (34.6) | 39 (11.0) | 120 (33.7) | 74 (20.8) | 61.858 | <0.001 |
Invasive Lobular | 13 (22.4) | 8 (13.8) | 4 (6.9) | 33 (56.9) | |||
Medullary-like | 2 (11.1) | 3 (16.7) | 9 (50.0) | 4 (22.2) | |||
Excellent Prognostic Special types* | 5 (25.0) | 6 (30.0) | 5 (25.0) | 4 (20.0) | |||
Tubular Mixed | 20 (20.6) | 11 (11.3) | 28 (28.9) | 38 (39.2) | |||
Mixed NST & Lobular | 4 (19.0) | 2 (9.5) | 6 (28.6) | 9 (42.9) | |||
Mixed NST &other special types | 2 (25.0) | 0 | 3 (37.5) | 3 (37.5) | |||